Clinical outcomes and adverse events of nontuberculous mycobacterial lung disease treated at an Italian tertiary referral center
Treatment of NTM lung disease (NTM-LD) is based on combinations of antimycobacterial drugs. It lasts 12 months if respiratory samples become culture negative, while in refractory cases it can last up to 18–24 months. Therapeutic pathway is complicated by frequent adverse events (AEs). Sometimes, sym...
Uloženo v:
| Vydáno v: | Scientific reports Ročník 15; číslo 1; s. 40133 - 11 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
Nature Publishing Group UK
17.11.2025
Nature Publishing Group Nature Portfolio |
| Témata: | |
| ISSN: | 2045-2322, 2045-2322 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Treatment of NTM lung disease (NTM-LD) is based on combinations of antimycobacterial drugs. It lasts 12 months if respiratory samples become culture negative, while in refractory cases it can last up to 18–24 months. Therapeutic pathway is complicated by frequent adverse events (AEs). Sometimes, symptomatic therapy is not sufficient to control AEs, making necessary to suspend the drug involved or the entire treatment. This study aims to describe the frequency and type of AEs in patients with NTM-LD and to evaluate their impact on the outcomes of treatment. This is a retrospective observational study. We analysed clinical data, regimen composition, AEs and outcomes of NTM-LD patients followed between January 2016 and June 2023 at the National Institute for Infectious Diseases “L. Spallanzani” in Rome. Out of 131 patients, fifty-eight (44.3%) were men; median age was 66 years (IQR: 56–73). One hundred (76.3%) developed AEs. Total AEs were 229, of which 81 were serious adverse events (SAEs). Cure was obtained in 113 cases (86.3%), therapeutic failure occurred in 10 (7.6%), 6 patients died (4.6%), and 2 (1.5%) were lost-to-follow-up. Despite of AEs, most patients were able to complete treatment with appropriate management and monitoring. AEs affect patient quality of life and treatment adherence. Therefore, it is important to identify factors that can predict and prevent them. Clear and detailed information about drug side effects, with instructions to follow in case of AEs, active monitoring at every contact, flexibility and accessibility to healthcare professionals are key factors for therapy success. |
|---|---|
| AbstractList | Treatment of NTM lung disease (NTM-LD) is based on combinations of antimycobacterial drugs. It lasts 12 months if respiratory samples become culture negative, while in refractory cases it can last up to 18–24 months. Therapeutic pathway is complicated by frequent adverse events (AEs). Sometimes, symptomatic therapy is not sufficient to control AEs, making necessary to suspend the drug involved or the entire treatment. This study aims to describe the frequency and type of AEs in patients with NTM-LD and to evaluate their impact on the outcomes of treatment. This is a retrospective observational study. We analysed clinical data, regimen composition, AEs and outcomes of NTM-LD patients followed between January 2016 and June 2023 at the National Institute for Infectious Diseases “L. Spallanzani” in Rome. Out of 131 patients, fifty-eight (44.3%) were men; median age was 66 years (IQR: 56–73). One hundred (76.3%) developed AEs. Total AEs were 229, of which 81 were serious adverse events (SAEs). Cure was obtained in 113 cases (86.3%), therapeutic failure occurred in 10 (7.6%), 6 patients died (4.6%), and 2 (1.5%) were lost-to-follow-up. Despite of AEs, most patients were able to complete treatment with appropriate management and monitoring. AEs affect patient quality of life and treatment adherence. Therefore, it is important to identify factors that can predict and prevent them. Clear and detailed information about drug side effects, with instructions to follow in case of AEs, active monitoring at every contact, flexibility and accessibility to healthcare professionals are key factors for therapy success. Treatment of NTM lung disease (NTM-LD) is based on combinations of antimycobacterial drugs. It lasts 12 months if respiratory samples become culture negative, while in refractory cases it can last up to 18-24 months. Therapeutic pathway is complicated by frequent adverse events (AEs). Sometimes, symptomatic therapy is not sufficient to control AEs, making necessary to suspend the drug involved or the entire treatment. This study aims to describe the frequency and type of AEs in patients with NTM-LD and to evaluate their impact on the outcomes of treatment. This is a retrospective observational study. We analysed clinical data, regimen composition, AEs and outcomes of NTM-LD patients followed between January 2016 and June 2023 at the National Institute for Infectious Diseases "L. Spallanzani" in Rome. Out of 131 patients, fifty-eight (44.3%) were men; median age was 66 years (IQR: 56-73). One hundred (76.3%) developed AEs. Total AEs were 229, of which 81 were serious adverse events (SAEs). Cure was obtained in 113 cases (86.3%), therapeutic failure occurred in 10 (7.6%), 6 patients died (4.6%), and 2 (1.5%) were lost-to-follow-up. Despite of AEs, most patients were able to complete treatment with appropriate management and monitoring. AEs affect patient quality of life and treatment adherence. Therefore, it is important to identify factors that can predict and prevent them. Clear and detailed information about drug side effects, with instructions to follow in case of AEs, active monitoring at every contact, flexibility and accessibility to healthcare professionals are key factors for therapy success.Treatment of NTM lung disease (NTM-LD) is based on combinations of antimycobacterial drugs. It lasts 12 months if respiratory samples become culture negative, while in refractory cases it can last up to 18-24 months. Therapeutic pathway is complicated by frequent adverse events (AEs). Sometimes, symptomatic therapy is not sufficient to control AEs, making necessary to suspend the drug involved or the entire treatment. This study aims to describe the frequency and type of AEs in patients with NTM-LD and to evaluate their impact on the outcomes of treatment. This is a retrospective observational study. We analysed clinical data, regimen composition, AEs and outcomes of NTM-LD patients followed between January 2016 and June 2023 at the National Institute for Infectious Diseases "L. Spallanzani" in Rome. Out of 131 patients, fifty-eight (44.3%) were men; median age was 66 years (IQR: 56-73). One hundred (76.3%) developed AEs. Total AEs were 229, of which 81 were serious adverse events (SAEs). Cure was obtained in 113 cases (86.3%), therapeutic failure occurred in 10 (7.6%), 6 patients died (4.6%), and 2 (1.5%) were lost-to-follow-up. Despite of AEs, most patients were able to complete treatment with appropriate management and monitoring. AEs affect patient quality of life and treatment adherence. Therefore, it is important to identify factors that can predict and prevent them. Clear and detailed information about drug side effects, with instructions to follow in case of AEs, active monitoring at every contact, flexibility and accessibility to healthcare professionals are key factors for therapy success. Abstract Treatment of NTM lung disease (NTM-LD) is based on combinations of antimycobacterial drugs. It lasts 12 months if respiratory samples become culture negative, while in refractory cases it can last up to 18–24 months. Therapeutic pathway is complicated by frequent adverse events (AEs). Sometimes, symptomatic therapy is not sufficient to control AEs, making necessary to suspend the drug involved or the entire treatment. This study aims to describe the frequency and type of AEs in patients with NTM-LD and to evaluate their impact on the outcomes of treatment. This is a retrospective observational study. We analysed clinical data, regimen composition, AEs and outcomes of NTM-LD patients followed between January 2016 and June 2023 at the National Institute for Infectious Diseases “L. Spallanzani” in Rome. Out of 131 patients, fifty-eight (44.3%) were men; median age was 66 years (IQR: 56–73). One hundred (76.3%) developed AEs. Total AEs were 229, of which 81 were serious adverse events (SAEs). Cure was obtained in 113 cases (86.3%), therapeutic failure occurred in 10 (7.6%), 6 patients died (4.6%), and 2 (1.5%) were lost-to-follow-up. Despite of AEs, most patients were able to complete treatment with appropriate management and monitoring. AEs affect patient quality of life and treatment adherence. Therefore, it is important to identify factors that can predict and prevent them. Clear and detailed information about drug side effects, with instructions to follow in case of AEs, active monitoring at every contact, flexibility and accessibility to healthcare professionals are key factors for therapy success. |
| ArticleNumber | 40133 |
| Author | Licata, Maria Angela Vittoria Mastrobattista, Annelisa Mazzarelli, Antonio Carli, Serena Maria Mencarini, Paola Cerva, Carlotta Vittozzi, Pietro Mosti, Silvia Musso, Maria Palmieri, Fabrizio Navarra, Assunta Gualano, Gina Ianniello, Stefania De Carli, Gabriella Nisii, Carla |
| Author_xml | – sequence: 1 givenname: Serena Maria surname: Carli fullname: Carli, Serena Maria organization: Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS – sequence: 2 givenname: Paola surname: Mencarini fullname: Mencarini, Paola email: paola.mencarini@inmi.it organization: Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS – sequence: 3 givenname: Maria Angela Vittoria surname: Licata fullname: Licata, Maria Angela Vittoria organization: Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS – sequence: 4 givenname: Maria surname: Musso fullname: Musso, Maria organization: Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS – sequence: 5 givenname: Carlotta surname: Cerva fullname: Cerva, Carlotta organization: Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS – sequence: 6 givenname: Annelisa surname: Mastrobattista fullname: Mastrobattista, Annelisa organization: Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS – sequence: 7 givenname: Pietro surname: Vittozzi fullname: Vittozzi, Pietro organization: Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS – sequence: 8 givenname: Silvia surname: Mosti fullname: Mosti, Silvia organization: Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS – sequence: 9 givenname: Carla surname: Nisii fullname: Nisii, Carla organization: Microbiology and Biobank Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS – sequence: 10 givenname: Antonio surname: Mazzarelli fullname: Mazzarelli, Antonio organization: Microbiology and Biobank Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS – sequence: 11 givenname: Assunta surname: Navarra fullname: Navarra, Assunta organization: Department of Epidemiology, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS – sequence: 12 givenname: Gabriella surname: De Carli fullname: De Carli, Gabriella organization: Department of Epidemiology, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS – sequence: 13 givenname: Stefania surname: Ianniello fullname: Ianniello, Stefania organization: Diagnostic Imaging Unit for Infectious Diseases, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS – sequence: 14 givenname: Fabrizio surname: Palmieri fullname: Palmieri, Fabrizio organization: Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS – sequence: 15 givenname: Gina surname: Gualano fullname: Gualano, Gina organization: Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/41249256$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UstuFDEQtFAQCUt-gAOyxIXLgJ_zOKIVj5UicYGz1fa0V7OaHQd7JlJufHp6d0JAHPClbauqulzul-xiShMy9lqK91Lo9kMx0nZtJZStlG5NU9XP2JUS5nRU6uKv_SW7LuUgaFnVGdm9YJdGKtMpW1-xX9txmIYAI0_LHNIRC4ep59DfYS7I8Q6nufAUObWfF485LGNaCj_eh-QhzJgH4o7LtOf9UBCIM2eEGUljJim-m2EcqBJyHiDf84wRcyZSIGnMr9jzCGPB68e6YT8-f_q-_VrdfPuy2368qYK2uq5aEL4HsNbX3gsqgvxHHb1twLTeahUojtijQQV1G2Kso25aBCGCEJ3QG7ZbdfsEB3ebhyOZcQkGd75Iee-AHIYRXR2wkShbCaI2EmvolYgW0RvZnIIjrXer1m1OPxcsszsOJeA4woQUjtOqUY3u1Lnt23-gh7TkiV56RrVSWHrfhr15RC3-iP2Tvd__RAC1AkJOpVCETxAp3Gke3DoPjubBnefBnUh6JRUCT3vMf3r_h_UAIwG4Uw |
| Cites_doi | 10.1093/cid/ciaa1361 10.1093/cid/cix517 10.1164/rccm.201908-1669OC 10.1183/13993003.02080-2016 10.5588/ijtld.11.0574 10.1093/cid/ciae421 10.1136/thoraxjnl-2017-210927 10.1016/j.rmed.2020.106164 10.1164/rccm.200510-1666ST 10.4415/ANN_23_02_06 10.3346/jkms.2020.35.e59 10.3201/eid2206.151086 10.3390/pathogens13040344) 10.1183/16000617.0299-2020 10.1183/13993003.00170-2018 10.1093/cid/ciaa252 10.1136/thoraxjnl-2015-207360 10.1183/16000617.0212-2021 10.3201/eid2403.171301 10.1093/cid/ciaa1125 10.1016/j.chest.2023.12.006 10.1016/j.rmed.2020.106089 10.1371/journal.pntd.0007083 10.5588/ijtld.17.0174 10.1164/rccm.201604-0681OC 10.1164/rccm.200407-863OC 10.1016/j.rmed.2020.105899 10.3389/fmicb.2018.02029 10.3389/fmicb.2024.1394220 10.1186/s12931-024-02752-y 10.1378/chest.11-1557 10.5588/ijtld.24.0068 10.5588/ijtld.18.0171 10.1186/s12879-021-06825-x 10.1186/s12890-022-02063-2 10.1007/s15010-024-02183-3 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025 2025. The Author(s). The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 DOA |
| DOI | 10.1038/s41598-025-23847-6 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_6ce71e181a0641e6ad20f5eeb4171249 41249256 10_1038_s41598_025_23847_6 |
| Genre | Journal Article Observational Study |
| GeographicLocations | Italy |
| GeographicLocations_xml | – name: Italy |
| GrantInformation_xml | – fundername: Italian Ministry of Health grantid: Ricerca Corrente grant of the IRCCS Research Program n.4 Tuberculosis and Nontuberculous Mycobacterial; Ricerca Corrente grant of the IRCCS Research Program n.4 Tuberculosis and Nontuberculous Mycobacterial; Ricerca Corrente grant of the IRCCS Research Program n.4 Tuberculosis and Nontuberculous Mycobacterial; Ricerca Corrente grant of the IRCCS Research Program n.4 Tuberculosis and Nontuberculous Mycobacterial; Ricerca Corrente grant of the IRCCS Research Program n.4 Tuberculosis and Nontuberculous Mycobacterial; Ricerca Corrente grant of the IRCCS Research Program n.4 Tuberculosis and Nontuberculous Mycobacterial; Ricerca Corrente grant of the IRCCS Research Program n.4 Tuberculosis and Nontuberculous Mycobacterial; Ricerca Corrente grant of the IRCCS Research Program n.4 Tuberculosis and Nontuberculous Mycobacterial; Ricerca Corrente grant of the IRCCS Research Program n.4 Tuberculosis and Nontuberculous Mycobacterial; Ricerca Corrente grant of the IRCCS Research Program n.4 Tuberculosis and Nontuberculous Mycobacterial; Ricerca Corrente grant of the IRCCS Research Program n.4 Tuberculosis and Nontuberculous Mycobacterial; Ricerca Corrente grant of the IRCCS Research Program n.4 Tuberculosis and Nontuberculous Mycobacterial; Ricerca Corrente grant of the IRCCS Research Program n.4 Tuberculosis and Nontuberculous Mycobacterial; Ricerca Corrente grant of the IRCCS Research Program n.4 Tuberculosis and Nontuberculous Mycobacterial; Ricerca Corrente grant of the IRCCS Research Program n.4 Tuberculosis and Nontuberculous Mycobacterial – fundername: Italian Ministry of Health grantid: Ricerca Corrente grant of the IRCCS Research Program n.4 Tuberculosis and Nontuberculous Mycobacterial |
| GroupedDBID | 0R~ 4.4 53G 5VS 7X7 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD AASML ABDBF ABUWG ACGFS ACUHS ADBBV ADRAZ AENEX AEUYN AFFHD AFKRA AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M1P M2P M7P M~E NAO OK1 PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7XB 88A 8FK K9. M48 PKEHL PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c3536-8a0bdaa55b6bb055b0925f3fb57a48b532c598fde4e2a68cff6f378ea00c00903 |
| IEDL.DBID | DOA |
| ISSN | 2045-2322 |
| IngestDate | Mon Nov 24 19:21:05 EST 2025 Tue Nov 18 17:32:20 EST 2025 Wed Nov 19 03:48:15 EST 2025 Fri Nov 21 01:40:36 EST 2025 Thu Nov 20 00:47:08 EST 2025 Tue Nov 18 01:10:28 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Nontuberculous mycobacterial lung disease treatment Adverse events Treatment outcome |
| Language | English |
| License | 2025. The Author(s). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3536-8a0bdaa55b6bb055b0925f3fb57a48b532c598fde4e2a68cff6f378ea00c00903 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://doaj.org/article/6ce71e181a0641e6ad20f5eeb4171249 |
| PMID | 41249256 |
| PQID | 3272810535 |
| PQPubID | 2041939 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6ce71e181a0641e6ad20f5eeb4171249 proquest_miscellaneous_3272739290 proquest_journals_3272810535 pubmed_primary_41249256 crossref_primary_10_1038_s41598_025_23847_6 springer_journals_10_1038_s41598_025_23847_6 |
| PublicationCentury | 2000 |
| PublicationDate | 20251117 |
| PublicationDateYYYYMMDD | 2025-11-17 |
| PublicationDate_xml | – month: 11 year: 2025 text: 20251117 day: 17 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2025 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | 23847_CR22 CL Daley (23847_CR6) 2020; 71 A Calcagno (23847_CR8) 2024; 52 23847_CR24 K Kumar (23847_CR29) 2022; 31 23847_CR7 JH Ku (23847_CR12) 2024; 165 G Abate (23847_CR26) 2021; 72 KL Winthrop (23847_CR17) 2020; 201 C Lin (23847_CR5) 2018; 24 DE Griffith (23847_CR37) 2005; 172 MW Carroll (23847_CR38) 2012; 16 N Veziris (23847_CR15) 2021; 21 S Aliberti (23847_CR16) 2020; 164 JY Kim (23847_CR40) 2022; 22 HJ Kim (23847_CR33) 2020; 171 WJ Koh (23847_CR19) 2012; 142 Y Kamii (23847_CR30) 2018; 22 N Kwak (23847_CR28) 2017; 65 YS Kwon (23847_CR36) 2020; 35 RA Floto (23847_CR9) 2016; 71 CL Daley (23847_CR18) 2017; 49 23847_CR34 23847_CR11 23847_CR13 LE Conyers (23847_CR23) 2024; 15 MA Campitelli (23847_CR27) 2019; 25 M Marmor (23847_CR25) 2024; 25 23847_CR32 DE Griffith (23847_CR35) 2005; 172 J van Ingen (23847_CR31) 2021; 73 SL Baldwin (23847_CR10) 2019; 13 23847_CR39 JR Honda (23847_CR1) 2018 5 (23847_CR20) 2016; 22 F Giannoni (23847_CR4) 2023; 59 CS Thornton (23847_CR2) 2021; 30 6 (23847_CR21) 2017; 195 BK Mohanty (23847_CR14) 2024; 13 JA Schildkraut (23847_CR3) 2020; 173 |
| References_xml | – volume: 73 start-page: e256 issue: 1 year: 2021 ident: 23847_CR31 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciaa1361 – volume: 65 start-page: 1077 issue: 7 year: 2017 ident: 23847_CR28 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/cix517 – volume: 201 start-page: 556 issue: 5 year: 2020 ident: 23847_CR17 publication-title: Am. J. Respir. Crit Care Med. doi: 10.1164/rccm.201908-1669OC – volume: 49 start-page: 1602080 issue: 3 year: 2017 ident: 23847_CR18 publication-title: Eur. Respir. J. doi: 10.1183/13993003.02080-2016 – volume: 16 start-page: 961 issue: 7 year: 2012 ident: 23847_CR38 publication-title: Int. J. Tuberc Lung Dis. doi: 10.5588/ijtld.11.0574 – ident: 23847_CR24 doi: 10.1093/cid/ciae421 – ident: 23847_CR7 doi: 10.1136/thoraxjnl-2017-210927 – volume: 173 start-page: 106164 year: 2020 ident: 23847_CR3 publication-title: Respir. Med. doi: 10.1016/j.rmed.2020.106164 – ident: 23847_CR34 doi: 10.1164/rccm.200510-1666ST – volume: 59 start-page: 132 issue: 2 year: 2023 ident: 23847_CR4 publication-title: Annali dell’Istituto Superiore Di sanità doi: 10.4415/ANN_23_02_06 – volume: 35 start-page: e59 issue: 9 year: 2020 ident: 23847_CR36 publication-title: J. Korean Med. Sci. doi: 10.3346/jkms.2020.35.e59 – volume: 22 start-page: 1116 issue: 6 year: 2016 ident: 23847_CR20 publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2206.151086 – volume: 13 start-page: 344 year: 2024 ident: 23847_CR14 publication-title: Pathogens doi: 10.3390/pathogens13040344) – volume: 30 start-page: 200299 issue: 160 year: 2021 ident: 23847_CR2 publication-title: Eur. Respir Rev. doi: 10.1183/16000617.0299-2020 – ident: 23847_CR13 doi: 10.1183/13993003.00170-2018 – volume: 72 start-page: 1127 year: 2021 ident: 23847_CR26 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciaa252 – volume: 71 start-page: i1 issue: Suppl 1 year: 2016 ident: 23847_CR9 publication-title: Thorax doi: 10.1136/thoraxjnl-2015-207360 – volume: 31 start-page: 210212 issue: 163 year: 2022 ident: 23847_CR29 publication-title: Eur. Respir Rev. doi: 10.1183/16000617.0212-2021 – volume: 24 start-page: 485 issue: 3 year: 2018 ident: 23847_CR5 publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2403.171301 – volume: 71 start-page: 905 issue: 4 year: 2020 ident: 23847_CR6 publication-title: Clin. Infect. Diseases: Official Publication Infect. Dis. Soc. Am. doi: 10.1093/cid/ciaa1125 – volume: 165 start-page: 1058 issue: 5 year: 2024 ident: 23847_CR12 publication-title: Chest doi: 10.1016/j.chest.2023.12.006 – volume: 171 start-page: 106089 year: 2020 ident: 23847_CR33 publication-title: Respir Med. doi: 10.1016/j.rmed.2020.106089 – volume: 13 start-page: e0007083 issue: 2 year: 2019 ident: 23847_CR10 publication-title: PLoS Negl. Trop. Dis. doi: 10.1371/journal.pntd.0007083 – ident: 23847_CR39 doi: 10.5588/ijtld.17.0174 – ident: 23847_CR11 – volume: 195 start-page: 783 issue: 6 year: 2017 ident: 23847_CR21 publication-title: Am. J. Respir. Crit Care Med. doi: 10.1164/rccm.201604-0681OC – volume: 172 start-page: 250 issue: 2 year: 2005 ident: 23847_CR37 publication-title: Am. J. Respir Crit. Care Med. doi: 10.1164/rccm.200407-863OC – volume: 164 start-page: 105899 year: 2020 ident: 23847_CR16 publication-title: Respir Med. doi: 10.1016/j.rmed.2020.105899 – volume: 25 start-page: 1271 year: 2019 ident: 23847_CR27 publication-title: Emerg. Infect. Dis. – ident: 23847_CR32 doi: 10.1016/j.chest.2023.12.006 – year: 2018 ident: 23847_CR1 doi: 10.3389/fmicb.2018.02029 – volume: 15 start-page: 1394220 year: 2024 ident: 23847_CR23 publication-title: Front. Microbiol. doi: 10.3389/fmicb.2024.1394220 – volume: 25 start-page: 123 issue: 1 year: 2024 ident: 23847_CR25 publication-title: Respir Res. doi: 10.1186/s12931-024-02752-y – volume: 142 start-page: 404 issue: 2 year: 2012 ident: 23847_CR19 publication-title: Chest doi: 10.1378/chest.11-1557 – ident: 23847_CR22 doi: 10.5588/ijtld.24.0068 – volume: 22 start-page: 1505 issue: 12 year: 2018 ident: 23847_CR30 publication-title: Int. J. Tuberc Lung Dis. doi: 10.5588/ijtld.18.0171 – volume: 172 start-page: 250 year: 2005 ident: 23847_CR35 publication-title: Am. J. Respir Crit. Care Med. doi: 10.1164/rccm.200407-863OC – volume: 21 start-page: 1165 issue: 1 year: 2021 ident: 23847_CR15 publication-title: BMC Infect. Dis. doi: 10.1186/s12879-021-06825-x – volume: 22 start-page: 269 issue: 1 year: 2022 ident: 23847_CR40 publication-title: BMC Pulm Med. doi: 10.1186/s12890-022-02063-2 – volume: 52 start-page: 737 issue: 3 year: 2024 ident: 23847_CR8 publication-title: Infection doi: 10.1007/s15010-024-02183-3 |
| SSID | ssj0000529419 |
| Score | 2.4640055 |
| Snippet | Treatment of NTM lung disease (NTM-LD) is based on combinations of antimycobacterial drugs. It lasts 12 months if respiratory samples become culture negative,... Abstract Treatment of NTM lung disease (NTM-LD) is based on combinations of antimycobacterial drugs. It lasts 12 months if respiratory samples become culture... |
| SourceID | doaj proquest pubmed crossref springer |
| SourceType | Open Website Aggregation Database Index Database Publisher |
| StartPage | 40133 |
| SubjectTerms | 631/326 692/1807 692/699 692/700 Adverse events Aged Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - therapeutic use Clinical outcomes Congenital diseases Data collection Drugs Female Generalized linear models Hospitals Humanities and Social Sciences Humans Infectious diseases Italy - epidemiology Laboratories Lung diseases Lung Diseases - drug therapy Lung Diseases - microbiology Male Medical records Medical treatment Middle Aged multidisciplinary Mycobacterium Infections, Nontuberculous - drug therapy Mycobacterium Infections, Nontuberculous - microbiology Nontuberculous Mycobacteria - drug effects Nontuberculous mycobacterial lung disease treatment Observational studies Pathogens Patients Quality of life Retrospective Studies Science Science (multidisciplinary) Side effects Tertiary Care Centers Treatment Outcome Tuberculosis |
| SummonAdditionalLinks | – databaseName: Science Database dbid: M2P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaggNQL70egICNxg6iOEz_2hABRwYGqB5B6syaOjSotm5JkK-2Nn86M490K8bhwipTY1sRjez7NjOdj7EWDoEDAIpZ6UcWyiWBLUNKWWsWqU1UdYwuJbMIcH9vT08VJdriNOa1yeyamg7rrPfnID2tppK2oGsnr8-8lsUZRdDVTaFxl1xDZVJTS9Ume7HwsFMVCYfJdGVHbwxHtFd0pk6pEW9WYUv9ij1LZ_j9hzd_ipMn8HN36X8Fvs5sZePI380q5w66E1V12Y6ai3NxjP3KB0CXv1xMOHEYOq44D8TWPgac6TyPvI1_1aKXaMPj1sl-P_NvG44mQKj5j3yUeHTzHfHjKYQ84xoRD8Y9T8qhwykE4g2HDE8HJgJ0oPzQM99mXo_ef330oMztD6WtFVYxBtB2AUq1uW4EPsZAq1rFVBhrbqlp6nOrYhSZI0NbHqGNtbAAhvCDv0AO2hyKHR4zrthPa26apgeKIEboGYRx4gGgQEoWCvdzqyJ3PRThcCp7X1s0adahRlzTqdMHekhp3LamAdnrRD19d3o9O-2CqgPAGEJNVQUMnRVQhtE1liI-7YAdbbbq8q0d3qcqCPd99xv1IQRZYBZz21MYQ6BQFezgvnp0kiekbMWbBXm1X0-Xgf_-hx_-W5Qnbl7SgKTfRHLC9aViHp-y6v5jOxuFZ2hE_Afd1E8k priority: 102 providerName: ProQuest |
| Title | Clinical outcomes and adverse events of nontuberculous mycobacterial lung disease treated at an Italian tertiary referral center |
| URI | https://link.springer.com/article/10.1038/s41598-025-23847-6 https://www.ncbi.nlm.nih.gov/pubmed/41249256 https://www.proquest.com/docview/3272810535 https://www.proquest.com/docview/3272739290 https://doaj.org/article/6ce71e181a0641e6ad20f5eeb4171249 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M7P dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: 7X7 dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: BENPR dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: PIMPY dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M2P dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEB_0TsEX8dvquUTwTculafPRR0_u8B5uWURhfSqTNIGDdU_arrBv_ulO0u56ouKLLym0SUgyM51JZvIbgFcVGQUc65Crugh5FdDkKIXJlQxFK4syBIsp2YSez81yWS-upfqKMWEjPPC4cMfKeV140kNIyrPwClvBg_TeVoWOiZPj35fr-tpmakT1FjUNY7olw0tz3JOmirfJhMxJS1U6V79oogTY_ycr8zcPaVI8Z_fg7mQxsrfjSO_DDb9-ALfHHJLbh_B9QvZcsavNQOzje4brlmFMtNx7lgCaenYVGO3zh431ndusaLfPvmwdiXKCaqa2K5J5NjlrWAo-99THQF2x8yEdhbAYPHCJ3ZalzCQdNYqBnb57BJ_OTj--e59PaRVyV8oIP4zctohSWmUtpwevhQxlsFJjZawshaOVCq2vvEBlXAgqlNp45NzxeKzzGA5oyP4pMGVbrpypqhKjAzBgW5H9hQ4xaLJlfAavd0vcfB3RM5rk9S5NMxKkIYI0iSCNyuAkUmFfMyJfpxfED83ED82_-CGDox0Nm0kc-6YUWpgiQtlk8HL_mQQpekdw7WnZUx0drUWewZOR9vuRpBTdZBxm8GbHDD87__uEnv2PCT2HOyJybQw91EdwMHQb_wJuuW_DZd_N4KZe6lSaGRyenM4XH2ZJFKi8EItYaioPF-cXi88_ABo9DHA |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VAoIL70eggJHgBFETJ3a8B4R4VV21rHooUm_GcWxUadmUJAvaG7-I38iMk2yFeNx64BQpD8tOPs988YznA3iSIylIzMTHcpL6OPdGxUZwFUvh00qkmfelCWITxWymjo4mBxvwY9wLQ2mVo00MhrqqLa2Rb2e84CqlaiQvT77EpBpF0dVRQqOHxZ5bfcNftvbF9C1-36ec77w7fLMbD6oCsc0EVd81SVkZI0QpyzLBQzLhwme-FIXJVSkybsVE-crljhuprPfSZ4VyJklsQqsa2O45OJ9TZTFKFeQH6zUdiprh4Ie9OUmmtlv0j7SHjYsYfWNexPIX_xdkAv7EbX-LywZ3t3P1f3tR1-DKQKzZq34mXIcNt7gBF3upzdVN-D4UQJ2zetnhQFzLzKJihvSoW8dCHauW1Z4tavTCpWvscl4vW_Z5ZdHihYrW-OwcTSMbYlos5Og7bKPDpti0CytGjHIsjk2zYkHApcGHKP_VNbfgw5kM_zZsYpfdXWCyrBJpVZ5nhuKk3lQ50lRjjfEFUj4XwbMRE_qkLzKiQ3JApnSPII0I0gFBWkbwmmCzvpMKhIcTdfNJD_ZGS-uK1CF9M8g5UydNxRMvnCvztCC98Qi2RvTowWq1-hQ6ETxeX0Z7Q0Eks3D42sM9BZHqJII7PVjXPQlK5sihI3g-ove08b8P6N6_-_IILu0evt_X-9PZ3n24zGkyUR5msQWbXbN0D-CC_dodt83DMBsZfDxrVP8EMi1xNQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lj9MwEB4tXUBceD8CCxgJThDVcWLHPSAELBXVQtUDSMvJOI6NVirNkqSg3vhd_DrGTtIV4nHbA6dITWLZ7ueZL57xfAAPMyQFVE9cLCaJizOnZaw5k7HgLil5kjpX6CA2kc_n8vBwstiBH8NZGJ9WOdjEYKjLyvg98nHKciYTX41k7Pq0iMX-9Nnxl9grSPlI6yCn0UHkwG6-4edb83S2j__1I8amr969fB33CgOxSbmvxKtpUWrNeSGKguKFThh3qSt4rjNZ8JQZPpGutJllWkjjnHBpLq2m1FC_w4HtnoFdpOQZG8HuYvZ28WG7w-NjaDgV_Ukdmspxg97Sn2hjPEZPmeWx-MUbBtGAPzHd36K0wflNL_3P03YZLvaUmzzv1sgV2LGrq3CuE-HcXIPvfWnUJanWLQ7KNkSvSqK9UnVjSahw1ZDKkVWF_rmwtVkvq3VDPm8M2sJQ6xrfXaLRJH20i4TsfYtttNgUmbVhL4n47IsjXW9IkHap8SWfGWvr6_D-VIZ_A0bYZXsLiChKKozMslT7CKrTZYYEVhutXY5k0EbweMCHOu7Kj6iQNpBK1aFJIZpUQJMSEbzwENo-6UuHhx-q-pPqLZESxuaJRWKnkY0mVuiSUcetLbIk90rkEewNSFK9PWvUCYwieLC9jZbIh5f0yuK0h2dyT7dpBDc74G57EjTOkV1H8GRA8knjfx_Q7X_35T6cRzCrN7P5wR24wPy68gma-R6M2npt78JZ87U9aup7_dIk8PG0Yf0TELF7fg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+outcomes+and+adverse+events+of+nontuberculous+mycobacterial+lung+disease+treated+at+an+Italian+tertiary+referral+center&rft.jtitle=Scientific+reports&rft.au=Carli%2C+Serena+Maria&rft.au=Mencarini%2C+Paola&rft.au=Licata%2C+Maria+Angela+Vittoria&rft.au=Musso%2C+Maria&rft.date=2025-11-17&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=15&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-025-23847-6&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |